Abstract
Objective: To determine the potential cost-effectiveness of 3 strategies for incorporation of bevacizumab (B) into the primary treatment of ovarian cancer: (1) standard platinum/taxane chemotherapy for all; (2) chemotherapy with concurrent and maintenance B for suboptimally debulked and stage IV disease (ICON 7 high risk cohort); (3) a predictive biomarker test that would identify a subset of women who derive survival advantage from the addition of B.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
